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LETTERS TO THE EDITOR
The Role of Lutein in the
Prevention of Atherosclerosis
McQuillan et al. (1) reported the findings of the Carotid Ultra-
sound Disease Assessment Study (CUDAS). They concluded that
the evidence for the use of supplemental vitamin antioxidant to
prevent atherosclerosis was limited, and this opinion was echoed by
Lonn (2) in an accompanying editorial. These findings are con-
sistent with another study where the evidence for a combination of
antioxidants (vitamin E, vitamin C, beta-carotene, and selenium)
in the prevention of coronary disease was rather tenuous (3).
Unfortunately, numerous compounds labeled as antioxidant vita-
mins are grouped together, and often the results are extrapolated
from one compound to another, implying that they all would yield
similar results. This can be misleading, given the favorable results
noted in another study investigating the xanthophyl carotenoid
lutein (4). The Los Angeles Atherosclerosis Study investigated the
progression of intima-media thickness of the common carotid
artery. Over an 18-month period, subjects with the highest serum
lutein level (0.42 mol/l) had 80% less arterial wall thickening
relative to those at the lowest quintile of serum lutein (0.15
mol/l). No such relationship was observed with serum beta-
carotene. Buttressing these findings were the animal experiments
reported in the same study, where lutein supplementation reduced
the size of atherosclerotic lesions in susceptible mice by 45% and
inhibited low-density lipoprotein (LDL) oxidation in a dose-
dependent manner up to almost 80%.
Moreover, complementary in vitro studies revealed that attrac-
tion of monocytes to oxidatively damaged human endothelial and
smooth muscle cells was dose-dependently inhibited in cells
incubated with lutein, with the inhibition of attraction up to
eight-fold more than cells incubated with LDL alone. Taken
together, these elegant findings suggest an important role for lutein
in the prevention of atherosclerosis (4).
We believe that the findings, and probably the interpretation, of
CUDAS could have been different had the investigators had the
opportunity to determine the levels of lutein in their cohort.
Moreover, it is well established that the bioavailability of lutein
from the diet is higher than that of beta-carotene (5–7). Conver-
sion of beta-carotene to retinol may be responsible for its low
plasma levels compared with those of lutein. In the Atherosclerosis
Risk in Communities (ARIC) study (8) it was also found that
there is a possible beneficial effect of a lutein-rich diet, which is
acknowledged by the CUDAS investigators.
Given the considerable interest in the prevention of early
atherosclerosis with antioxidants, it is important to ferret out those
that may have beneficial actions and those that do not. Grouping
together various agents under a broad category can be misleading.
Although statins have often been discussed as a class, the experi-
ence with cerivastatin (9) should reinforce the contention that all
compounds within the same pharmacologic class are not equiva-
lent—some may be beneficial while others may be harmful or
relatively ineffective. Similarly, there are various antioxidants and
carotenoids, and although some may not play a role in early
protection against atherosclerosis, others, like lutein, may indeed
have a protective role.
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REPLY
We were very interested in the comments by Drs. Alves-Rodrigues
and Thomas regarding the variable results of studies examining the
relationship between antioxidant vitamins and atherosclerosis. As
they point out, it would be inappropriate to dismiss all antioxidant
vitamins with regards to their potential anti-atherogenic properties
based on data that demonstrates only weak or no effects for a
limited range of vitamins studied. Our study assessed the relation-
ship of dietary intake or plasma levels of a number of antioxidant
vitamins with subclinical carotid atherosclerosis in a large (N 
1,111 subjects) randomly selected community population (1). We
selected vitamins that are relatively plentiful in Western diets and
have been suggested as important antioxidant compounds in
studies of lipid oxidation and animal models of atherosclerosis. We
observed a weak inverse association between dietary intake of
vitamin E and common carotid artery intimal-medial thickness
(IMT) in men, with a nonsignificant trend in women. An inverse
association was also found between carotid IMT and plasma
lycopene in women but not in men. We did not assess dietary
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intake or plasma levels of lutein in our study, although this could
be undertaken.
A number of epidemiologic studies have now demonstrated an
association between dietary intake or plasma levels of antioxidant
vitamins and the risk of atherosclerotic vascular disease. However,
large-scale randomized trials to test further for a causal relationship
between antioxidant intake and ischemic heart disease have pro-
vided conflicting results (2). Although there is plausible biological
evidence to suggest antioxidants may prevent the early stages of
atherogenesis, it is unknown as to whether they alter the later
processes that produce clinical events. To determine the role of
antioxidant vitamins in atherosclerosis, it may be more appropriate
to examine the relationship between dietary intake or plasma levels
of these vitamins and measures of early atherosclerosis rather than
clinical cardiovascular events (3).
Although we remain very interested in investigating antioxidant
defenses against lipid peroxidation and novel risk factors for
atherosclerosis, we would support the concept that this essential
ongoing research should not distract us from efforts to implement
more proven preventive strategies (4).
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Controlling the Effectiveness of Digoxin
In a recent issue of the Journal, Adams, et al. (1) correctly stated
that: “Patients taking digoxin did significantly better than those
not taking the drug, but the serum concentration did not correlate
with outcome.” Nevertheless, they concluded: “These results sup-
port the possibility that a lower therapeutic goal for serum digoxin
concentration is warranted in patients with heart failure.”
This conclusion is flawed because in individual patients the
concentration of digoxin in the serum does not accurately represent
the amount of digoxin in the tissues where it works. The digoxin
in the serum is only a tiny fraction of the total amount of digoxin
in the body. The total amount of digoxin in the body is easy to
calculate from the doses administered, and it does correlate with
outcome (2–4). Guiding dosage this way allowed high doses of
digoxin (15 to 19 g/kg of lean body weight) to be given to
patients after cardiac operations, and the patients recovered rapidly
(5,6).
Because serum digoxin concentrations poorly guide dosage and
results, contradictions between serum levels and results have been
seen by many doctors. Low serum concentrations of digoxin
appeared in patients who received therapeutic benefits. In contrast,
high serum concentrations of 2.5 ng/ml have been seen in patients
who had no signs or symptoms of toxicity.
Dr. Jelliffe published a method for calculating the milligrams of
digoxin needed to produce a specific peak total body load of
digoxin and to engender a desired therapeutic result (2–4). A safe,
effective amount of peak total body digoxin to treat heart failure is
8 to 10 g/kg of lean body weight. This program is used at the
University of Southern California/Los Angeles County Medical
Center and at several other hospitals.
Studying the effects of digoxin requires knowing the total
amount of digoxin in the body, which controls the amount of
digoxin in the tissues where digoxin works.
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We appreciate Dr. Krohn’s interest and comments concerning our
analysis. We believe our conclusions as stated in the study are
correct. While it is true that the serum digoxin concentration
(SDC) is significantly higher than the tissue concentration during
the distributive phase of digoxin dosing (6 to 12 h), both the SDC
and the amount of drug in the body decline in parallel and are
directly related 12 to 24 h post-dose (1). This is the rationale for
the recommendation to always draw the SDC as a trough
concentration—that is, 24 h after the dose (2). This was mandated
in both the PROVED and RADIANCE protocols.
We agree with Dr. Krohn’s statement that total body stores of
digoxin are easy to calculate. Unfortunately, we are unable to do
this for each individual patient in these studies. However, the
dosing guidelines cited by Dr. Krohn are incorporated into the
dosing table that is currently included in the Lanoxin package
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